Stock 600479 ZHUZHOU QIANJIN PHARMACEUTICAL CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials ZhuZhou QianJin Pharmaceutical Co.,Ltd

Equities

600479

CNE000001GX3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
11.55 CNY +1.67% Intraday chart for ZhuZhou QianJin Pharmaceutical Co.,Ltd +1.85% +7.24%
Apr. 29 ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jan. 24 Qianjin Pharma Unit Gets Nod for Supplemental New Drug Application for Teralithe Biosimilar MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,248 3,670 3,616 5,252 4,126 4,619
Enterprise Value (EV) 1 2,111 2,315 2,263 3,980 2,337 2,738
P/E ratio 12.7 x 12.5 x 12.2 x 17.4 x 13.5 x 14.2 x
Yield 5.15% 5.7% 11.6% 4.78% 3.65% 3.25%
Capitalization / Revenue 0.98 x 1.04 x 1 x 1.43 x 1.02 x 1.22 x
EV / Revenue 0.63 x 0.66 x 0.62 x 1.09 x 0.58 x 0.72 x
EV / EBITDA 6.25 x 5.82 x 5.68 x 9.54 x 4.95 x 6.02 x
EV / FCF 9.17 x 9.65 x 9.89 x 11.9 x 3.26 x 10.9 x
FCF Yield 10.9% 10.4% 10.1% 8.39% 30.7% 9.2%
Price to Book 1.6 x 1.69 x 1.6 x 2.44 x 1.85 x 1.93 x
Nbr of stocks (in thousands) 418,507 418,507 418,507 418,507 429,807 428,917
Reference price 2 7.760 8.770 8.640 12.55 9.600 10.77
Announcement Date 4/11/19 4/9/20 4/14/21 4/14/22 4/12/23 4/11/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 3,329 3,525 3,627 3,664 4,026 3,798
EBITDA 1 337.6 397.9 398.4 417.2 472.1 455.1
EBIT 1 276.9 338.1 338.9 354.6 404.9 376.4
Operating Margin 8.32% 9.59% 9.34% 9.68% 10.06% 9.91%
Earnings before Tax (EBT) 1 352.3 429.7 424.6 433.4 445.8 460.4
Net income 1 255.4 294.3 297.1 302.1 303.6 320.4
Net margin 7.67% 8.35% 8.19% 8.24% 7.54% 8.44%
EPS 2 0.6102 0.7032 0.7098 0.7218 0.7093 0.7583
Free Cash Flow 1 230.3 240 228.9 334 716.2 252.1
FCF margin 6.92% 6.81% 6.31% 9.11% 17.79% 6.64%
FCF Conversion (EBITDA) 68.21% 60.31% 57.46% 80.04% 151.7% 55.39%
FCF Conversion (Net income) 90.19% 81.54% 77.06% 110.56% 235.88% 78.67%
Dividend per Share 2 0.4000 0.5000 1.000 0.6000 0.3500 0.3500
Announcement Date 4/11/19 4/9/20 4/14/21 4/14/22 4/12/23 4/11/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,136 1,356 1,353 1,273 1,789 1,881
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 230 240 229 334 716 252
ROE (net income / shareholders' equity) 13% 13.9% 13.4% 13.7% 14.1% 13.5%
ROA (Net income/ Total Assets) 5.12% 5.8% 5.27% 5.35% 5.83% 5.05%
Assets 1 4,987 5,073 5,639 5,649 5,209 6,341
Book Value Per Share 2 4.850 5.200 5.420 5.140 5.180 5.570
Cash Flow per Share 2 2.370 3.290 1.800 1.510 2.900 4.660
Capex 1 46.4 40.6 97.2 71.9 34.4 44
Capex / Sales 1.39% 1.15% 2.68% 1.96% 0.86% 1.16%
Announcement Date 4/11/19 4/9/20 4/14/21 4/14/22 4/12/23 4/11/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHUZHOU QIANJIN PHARMACEUTICAL CO.,LTD Stock ZhuZhou QianJin Pharmaceutical Co.,Ltd
+7.24% 685M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600479 Stock
  4. Financials ZhuZhou QianJin Pharmaceutical Co.,Ltd